| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human PD-1/PDCD1/CD279-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human PD-1 at 5 Mu g/mL (100 Mu L/well) can bind Recombinant Human PD-L1 with a linear range of 0.5-2 Mu g/mL. |
| Gene Symbol: |
PDCD1 |
| Gene ID: |
5133 |
| Uniprot ID: |
PDCD1_HUMAN |
| Immunogen: |
Recombinant Human PD-1/PDCD1/CD279 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Leu25-Thr168) of human PD-1 (Accession #NP_005009.2) fused with a 6×His tag at the C-terminus. |
| Post Translational Modifications | Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation. Ubiquitinated via 'Lys-48'-linked polyubiquitin chains. Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. N-glycosylation at Asn-58 contains at least two N-acetylglucosamine units and one fucose. N-glycosylation does not affect binding to nivolumab drug. |
| Function | Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Protein Name | Programmed Cell Death Protein 1Protein Pd-1Hpd-1Cd Antigen Cd279 |
| Database Links | Reactome: R-HSA-389948Reactome: R-HSA-9679191 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
| Alternative Protein Names | Programmed Cell Death Protein 1 proteinProtein Pd-1 proteinHpd-1 proteinCd Antigen Cd279 proteinPDCD1 proteinPD1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
